Cargando…
晚期非小细胞肺癌免疫治疗的一线联合治疗
Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor has become one of the important treatment options for patients with advanced non-small cell lung cancer (NSCLC). However, only a small subset of patients with NSCLC can currently receive single-agent PD-1 inhibitors as first-line th...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318566/ https://www.ncbi.nlm.nih.gov/pubmed/30591101 http://dx.doi.org/10.3779/j.issn.1009-3419.2018.12.11 |